Suggested remit: To appraise the clinical and cost effectiveness of levodopa, carbidopa monohydrate and entacapone within its marketing authorisation for treating the symptoms of advanced Parkinson’s disease
|
Status
|
Topic selection
|
|
Technology type
|
Medicine
|
|
Decision
|
Not selected
|
|
Reason for decision
|
Not eligible for Health Technology Evaluation guidance
|
| ID number |
4005
|
Project Team
| Project lead |
Michelle Adhemar |
Email enquiries
|
Date
|
Update
|
|
20 July 2022
|
The NICE Topic Selection Oversight Panel (TSOP), met in June 2022 to carefully consider the suitability of this topic for a Technology Appraisal (TA). The panel concluded it would not be an efficient use of NHS resources to conduct an evaluation. The topic will be formally removed from the NICE work programme. Due to the non-selection, NHS England may consider the technology for routine commissioning – please see section 3.1 of the NHS England Procedural note: non submission of data to NICE for further information. Any request for consideration for routine commissioning needs to be submitted via a clinician; the Service Development Policy outlines the process. |
|
11 July 2022
|
Topic selection. Change TS decision to deselected |
|
03 May 2022 (10:00)
|
Scoping workshop |
|
15 March 2022 - 12 April 2022
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
15 March 2022
|
In progress. Scoping commenced |
|
15 March 2022
|
In progress. Scoping commenced |
|
28 January 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on how we select topics for development, please see our page about topic selection